共识指南 第133页
排序
![2023NICE技术鉴定指导意见：瑞培替尼治疗3次或以上治疗后的晚期胃肠道间质瘤[TA881]-医知素材库](https://cdn.jiaoyuwz.com/2023NICE技术鉴定指导意见：瑞培替尼治疗3次或以上治疗后的晚期胃肠道间质瘤[TA881]-3612245c62-pdf-1.webp)
2023NICE技术鉴定指导意见：瑞培替尼治疗3次或以上治疗后的晚期胃肠道间质瘤[TA881]
NCENaiional nstitute forHealth and Care ExcellenceNICE贝guidanceRipretinib for treatingadvanced gastrointestinalstromal tumour after 3 ormore treatmentsTechnology appraisal guidanc...
会员专属
![2023NICE技术鉴定指导意见：瑞戈非尼用于既往治疗过的转移性结直肠癌[TA866]-医知素材库](https://cdn.jiaoyuwz.com/2023NICE技术鉴定指导意见：瑞戈非尼用于既往治疗过的转移性结直肠癌[TA866]-15bf905dbd-pdf-1.webp)
2023NICE技术鉴定指导意见：瑞戈非尼用于既往治疗过的转移性结直肠癌[TA866]
NICENational Institute forHealth and Care ExcellenceNICE贝guidanceRegorafenib for previouslytreated metastaticcolorectal cancerTechnology appraisal guidancePublished:8 February 202...
![2023NICE技术鉴定指导意见：曲妥珠单抗deruxtecan用于在1次或多次抗HER2治疗后治疗HER2阳性不可切除或转移性乳腺癌[TA862]-医知素材库](https://cdn.jiaoyuwz.com/2023NICE技术鉴定指导意见：曲妥珠单抗deruxtecan用于在1次或多次抗HER2治疗后治疗HER2阳性不可切除或转移性乳腺癌[TA862]-816b7b06b5-pdf-1.webp)
2023NICE技术鉴定指导意见：曲妥珠单抗deruxtecan用于在1次或多次抗HER2治疗后治疗HER2阳性不可切除或转移性乳腺癌[TA862]
NENatonalinsutute forHealth and Care ExcellenceNICE贝guidanceTrastuzumab deruxtecanfor treating HER2-positiveunresectable or metastaticbreast cancer after 1 ormore anti-HER2treatme...
![2023NICE技术鉴定指导意见：泊洛妥珠单抗-维布妥昔单抗联合治疗未经治疗的弥漫性大B细胞淋巴瘤[TA874]-医知素材库](https://cdn.jiaoyuwz.com/2023NICE技术鉴定指导意见：泊洛妥珠单抗-维布妥昔单抗联合治疗未经治疗的弥漫性大B细胞淋巴瘤[TA874]-7a4a756b81-pdf-1.webp)
2023NICE技术鉴定指导意见：泊洛妥珠单抗-维布妥昔单抗联合治疗未经治疗的弥漫性大B细胞淋巴瘤[TA874]
NENatonalinsutute forHealth and Care ExcellenceNICE贝guidancePolatuzumab vedotin incombination for untreateddiffuse large B-celllymphomaTechnology appraisal guidancePublished:1 Mar...
![2023NICE技术鉴定指导意见：纳武单抗联合化疗用于可切除非小细胞肺癌的新辅助治疗[TA876]-医知素材库](https://cdn.jiaoyuwz.com/2023NICE技术鉴定指导意见：纳武单抗联合化疗用于可切除非小细胞肺癌的新辅助治疗[TA876]-d0b06576c7-pdf-1.webp)
2023NICE技术鉴定指导意见：纳武单抗联合化疗用于可切除非小细胞肺癌的新辅助治疗[TA876]
NENatonalinsutute forHealth and Care ExcellenceNICE贝guidanceNivolumab withchemotherapy forneoadjuvant treatment ofresectable non-small-celllung cancerTechnology appraisal guidance...
![2023NICE技术鉴定指导意见：派姆单抗联合化疗联合或不联合贝伐单抗治疗持续性、复发性或转移性宫颈癌[TA885]-医知素材库](https://cdn.jiaoyuwz.com/2023NICE技术鉴定指导意见：派姆单抗联合化疗联合或不联合贝伐单抗治疗持续性、复发性或转移性宫颈癌[TA885]-b59502e641-pdf-1.webp)
2023NICE技术鉴定指导意见：派姆单抗联合化疗联合或不联合贝伐单抗治疗持续性、复发性或转移性宫颈癌[TA885]
NENatonalinsutute forHealth and Care ExcellenceNICE贝guidancePembrolizumab pluschemotherapy with orwithout bevacizumab forpersistent,recurrent ormetastatic cervical cancerTechnolog...
2023NICE技术鉴定指导意见：纳武单抗联合氟嘧啶类和铂类化疗治疗未经治疗的不可切除的晚期、复发性或转移性食管鳞状细胞癌TA865
NENatonalinsutute forHealth and Care ExcellenceNICE贝guidanceNivolumab withfluoropyrimidine-andplatinum-basedchemotherapy foruntreated unresectableadvanced,recurrent,ormetastatic o...
![2023NICE技术鉴定指导意见：纳武单抗联合铂类和氟嘧啶类化疗治疗未经治疗的HER2阴性晚期胃癌、胃食管交界处癌或食管腺癌[TA857]-医知素材库](https://cdn.jiaoyuwz.com/2023NICE技术鉴定指导意见：纳武单抗联合铂类和氟嘧啶类化疗治疗未经治疗的HER2阴性晚期胃癌、胃食管交界处癌或食管腺癌[TA857]-a0a6541175-pdf-1.webp)
2023NICE技术鉴定指导意见：纳武单抗联合铂类和氟嘧啶类化疗治疗未经治疗的HER2阴性晚期胃癌、胃食管交界处癌或食管腺癌[TA857]
NCE Naonaltitute forHealth and Care ExcellenceNICE贝guidanceNivolumab with platinum-and fluoropyrimidine-based chemotherapy foruntreated HER2-negativeadvanced gastric,gastro-oesoph...
![2023NICE技术鉴定指导意见：乐伐替尼联合派姆单抗治疗未经治疗的晚期肾细胞癌[TA858]-医知素材库](https://cdn.jiaoyuwz.com/2023NICE技术鉴定指导意见：乐伐替尼联合派姆单抗治疗未经治疗的晚期肾细胞癌[TA858]-ad7f1cbb23-pdf-1.webp)
2023NICE技术鉴定指导意见：乐伐替尼联合派姆单抗治疗未经治疗的晚期肾细胞癌[TA858]
NENatonalinsutute forHealth and Care ExcellenceNICE贝guidanceLenvatinib withpembrolizumab foruntreated advanced renalcell carcinomaTechnology appraisal guidancePublished:11 January...
![2023NICE技术鉴定指导意见：奥拉帕尼用于既往治疗过的BRCA突变阳性激素复发转移性前列腺癌[TA887]-医知素材库](https://cdn.jiaoyuwz.com/2023NICE技术鉴定指导意见：奥拉帕尼用于既往治疗过的BRCA突变阳性激素复发转移性前列腺癌[TA887]-15c6a9fc69-pdf-1.webp)
2023NICE技术鉴定指导意见：奥拉帕尼用于既往治疗过的BRCA突变阳性激素复发转移性前列腺癌[TA887]
NENational nstitute forHealth and Care ExcellenceNICE贝guidanceOlaparib for previouslytreated BRCA mutation-positive hormone-relapsedmetastatic prostate cancerTechnology appraisal ...
